COST-EFFECTIVENESS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN AUSTRALIA

被引：0
|
作者：
Tilden, D. [1 ]
Germanos, P. [2 ]
Gordon, J. [2 ]
Tocchini, L. [1 ]
Monz, B. [3 ]
机构：
[1] THEMA Consulting Pty Ltd, Pyrmont, NSW, Australia
[2] Boehringer Ingelheim Pty Ltd, N Ryde, NSW, Australia
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.781
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A375 / A375
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [22] STROKE PROPHYLAXIS WITH WARFARIN AND DABIGATRAN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION - A COST ANALYSIS
    Ali, A. N.
    Bailey, C.
    Abdulhafiz, A. H.
    [J]. AGE AND AGEING, 2013, 42 : 31 - 31
  • [23] Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China
    Zhou, Hui
    Nie, Xiaoning
    Jiang, Minghuan
    Dong, Weihua
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (04) : 523 - 530
  • [24] Cost-effectiveness of dabigatran etexilate versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation under the public and private healthcare system in Brazil
    Nasciben, V. D.
    Giangrande, L.
    Piegas, L.
    Figueiredo, M.
    Darrieux, F.
    Martins, S.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 : 58 - 58
  • [25] Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain
    Escolar-Albaladejo, Gines
    Baron-Esquivias, Gonzalo
    Luis Zamorano, Jose
    Betegon-Nicolas, Lourdes
    Canal-Fontcuberta, Cristina
    de Salas-Cansado, Marina
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    [J]. ATENCION PRIMARIA, 2016, 48 (06): : 394 - 405
  • [26] COST-EFFECTIVENESS OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN CHINA
    Wan, Y.
    Davies, G. M.
    Lu, Z. G.
    Chen, F.
    Chen, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A114 - A114
  • [27] Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
    Pletscher, Mark
    Plessow, Rafael
    Eichler, Klaus
    Wieser, Simon
    [J]. SWISS MEDICAL WEEKLY, 2013, 143
  • [28] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Krejczy, Martin
    Harenberg, Job
    Marx, Svetlana
    Obermann, Konrad
    Froelich, Lutz
    Wehling, Martin
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 37 (04) : 507 - 523
  • [29] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Martin Krejczy
    Job Harenberg
    Svetlana Marx
    Konrad Obermann
    Lutz Frölich
    Martin Wehling
    [J]. Journal of Thrombosis and Thrombolysis, 2014, 37 : 507 - 523
  • [30] Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lievens Annemans
    Vincent Thijs
    Sophie Marbaix
    [J]. Clinical Drug Investigation, 2014, 34 : 709 - 721
12345